Factors influencing acute rejection of human hand allografts: A systematic review

Annals of Plastic Surgery

Volumn 68, Issue 6, 2012, Pages 624-629

  Bonastre, Jorge ^a   Landin, Luis ^a   Diez, Jesus ^a   Casado Sanchez, Cesar ^a   Casado Perez, Cesar ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

composite tissue allograft; cytomegalovirus; hand allograft; rejection; tacrolimus; vascularized composite allograft

Indexed keywords

HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; STEROID;

ALLOTRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; EPIDEMIOLOGY; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HAND; HUMAN; IMMUNOLOGY; METHODOLOGY; PLASTIC SURGERY; REVIEW; RISK FACTOR; TRANSPLANTATION;

CAUSALITY; CYTOMEGALOVIRUS INFECTIONS; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HAND; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECONSTRUCTIVE SURGICAL PROCEDURES; RISK FACTORS; STEROIDS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84861682926     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/SAP.0b013e318255a411     Document Type: Review

References (72)

1. Kaufman CL, Blair B, Murphy E, et al. A new option for amputees: transplantation of the hand. J Rehabil Res Dev. 2009;46:395-404.
2. Schneeberger S, Landin L, Jableki J, et al. Achievements and challenges in composite tissue allotransplantation. Transpl Int. 2011;24:760-769.
3. Petruzzo P, Kanitakis J, Badet L, et al. Long-term follow-up in composite tissue allotransplantation: in-depth study of five (hand and face) recipients. Am J Transplant. 2011;11:808-816.
4. Breidenbach WC, Gonzales NR, Kaufman CL, et al. Outcomes of the first 2 American hand transplants at 8 and 6 years posttransplant. J Hand Surg Am. 2008;33:1039-1047.
5. Landin L, Bonastre J, Casado-Sanchez C, et al. Outcomes with respect to disabilities of the upper limb after hand allograft transplantation: a systematic review. Transpl Int. 2012;25:424-432.
6. Paramesh AS, Zhang R, Baber J, et al. The effect of HLA mismatch on highly sensitized renal allograft recipients. Clin Transplant. 2010;24:E247YE252.
7. Wu O, Levy AR, Briggs A, et al. Acute rejection and chronic nephropathy: a systematic review of the literature. Transplantation. 2009;87:1330-1339.
8. Landin L, Cavadas PC, Garcia-Cosmes P, et al. Perioperative ischemic injury and fibrotic degeneration of muscle in a forearm allograft: functional follow-up at 32 months post transplantation. Ann Plast Surg. 2011;66:202-209.
9. Schneeberger S, Ninkovic M, Gabl M, et al. First forearm transplantation: outcome at 3 years. Am J Transplant. 2007;7:1753-1762.
10. Jablecki J, Kaczmarzyk L, Patrzalek D, et al. Mild rejection episode evoked by modification of immunosuppressive protocol observed in a patient with forearm transplantation: case report. Transplant Proc. 2009;41:557-559.
11. Landymore R, Murphy JT, Hall R, et al. Randomized trial comparing intermittent antegrade warm blood cardioplegia with multidose cold blood cardioplegia for coronary artery bypass. Eur J Cardiothorac Surg. 1996;10:179-184.
12. Camara AK, Riess ML, Kevin LG, et al. Hypothermia augments reactive oxygen species detected in the guinea pig isolated perfused heart. Am J Physiol Heart Circ Physiol. 2004;286:H1289YH1299.
13. Jacobs S, Rega F, Meyns B. Current preservation technology and future prospects of thoracic organs. Part 2: heart. Curr Opin Organ Transplant. 2010;15:156-159.
14. Christie JD, Edwards LB, Aurora P, et al. The registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation ReportV2009. J Heart Lung Transplant. 2009; 28:1031-1049.
15. Petruzzo P, Lanzetta M, Dubernard JM, et al. The international registry on hand and composite tissue transplantation. Transplantation. 2010;90:1590-1594.
16. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(suppl 3):10-13.
17. Salgo R, Gossmann J, Schofer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10:1385-1393.
18. Watson CJ, Gimson AE, Alexander GJ, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl. 2007;13:1694-1702.
19. Augustine JJ, Hricik DE. Minimization of immunosuppression in kidney transplantation. Curr Opin Nephrol Hypertens. 2007;16:535-541.
20. Augustine JJ, Hricik DE. Steroid withdrawal: moving on to the next questions. Am J Transplant. 2009;9:3-4.
21. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248: 564-577.
22. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008;8:307-316.
23. Jankowska-Gan E, Sollinger HW, Pirsch JD, et al. Successful reduction of immunosuppression in older renal transplant recipients who exhibit donorspecific regulation. Transplantation. 2009;88:533-541.
24. Morris PJ, Johnson RJ, Fuggle SV, et al. Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK. HLA Task Force of the Kidney Advisory Group of the United Kingdom Transplant Support Service Authority (UKTSSA). Lancet. 1999;354:1147-1152.
25. Opelz G, Dohler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation. 2007;84:137-143.
26. Evans PC, Soin A, Wreghitt TG, et al. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation. 2000;69:30-35.
27. Schneeberger S, Lucchina S, Lanzetta M, et al. Cytomegalovirus-related complications in human hand transplantation. Transplantation. 2005;80:441-447.
28. Baldanti F, Lucchini G, Lilleri D, et al. Sustained impairment of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cell response is responsible for recurrent episodes of disseminated HCMV infection in a D+Rj hand transplant recipient. Cases J. 2008;1:155.
29. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008;358:353-361.
30. Barth RN, Rodriguez ED, Mundinger GS, et al. Vascularized bone marrowbased immunosuppression inhibits rejection of vascularized composite allografts in nonhuman primates. Am J Transplant. 2011;11:1407-1416.
31. Huang WC, Liao SK,Wallace CG, et al. Greater efficacy of tolerance induction with cyclosporine versus tacrolimus in composite tissue allotransplants with less myeloablative conditioning. Plast Reconstr Surg. 2011;127:1141-1148.
32. Gordon CR, Siemionow M, Papay F, et al. The world's experience with facial transplantation: what have we learned thus far? Ann Plast Surg. 2009;63: 572-578.
33. Jablecki J, Kaczmarzyk L, Domanasiewicz A, et al. Hand transplant outcome after 6 months, preliminary report. Ortop Traumatol Rehabil. 2010;12:90-99.
34. Schneeberger S, Brandacher G, Gorantla VS, et al. The Pittsburgh Hand Transplant ProgramVEarly Experience With a Novel Immunomodulatory Protocol in Two Patients. San Diego, CA: American Transplant Congress; 2010:180.
35. Schneeberger S, Kreczy A, Brandacher G, et al. Steroid- and ATG-resistant rejection after double forearm transplantation responds to Campath-1H. Am J Transplant. 2004;4:1372-1374.
36. Dubernard JM, Owen E, Herzberg G, et al. Human hand allograft: report on first 6 months. Lancet. 1999;353:1315-1320.
37. Landin L, Cavadas PC, Nthumba P, et al. Morphological and functional evaluation of visual disturbances in a bilateral hand allograft recipient. J Plast Reconstr Aesthet Surg. 2010;63:700-704.
38. Breidenbach WCRK, Buell J, Kaufman C. Update on the American Hand Transplant Experience: Five Hand Transplants Performed in Louisville. Boston, MA: American Transplant Congress; 2009:129.
39. Breidenbach WCHR, Kaufman C, Slone S, et al. An Unusual PTLD-Like Syndrome in Hand Transplant Recipient 2 Years Post Transplant. Boston, MA: American Transplant Congress; 2009:128.
40. Dubernard JM, Petruzzo P, Lanzetta M, et al. Functional results of the first human double-hand transplantation. Ann Surg. 2003;238:128-136.
41. Breidenbach W, Ravindra K, Blair B, et al. Transplant Arteriopathy in Clinical Hand Transplantation. Valencia, Spain: 9th Meeting of the International Hand and Composite Tissue Allotransplantation Society; 2009:11-12.
42. Pondrom S. Arms, ovaries and tracheasIwhat next? Am J Transplant. 2009; 9:438.
43. Pinzur MS, Pinto MA, Schon LC, et al. Controversies in amputation surgery. Instr Course Lect. 2003;52:445-451.
44. Datta D, Selvarajah K, Davey N. Functional outcome of patients with proximal upper limb deficiencyVacquired and congenital. Clin Rehabil. 2004;18:172-177.
45. Chung KC, Oda T, Saddawi-Konefka D, et al. An economic analysis of hand transplantation in the United States. Plast Reconstr Surg. 2010;125:589-598.
46. Cavadas PC, Landin L, Thione A, et al. Improvement of the disabilities of the upper limb after hand allograft transplantation: outcomes after hand, forearm, and arm transplantation. Hand Clin. 2011;27:443-453.
47. Yilmaz S, Koskinen PK, Kallio E, et al. Cytomegalovirus infection-enhanced chronic kidney allograft rejection is linked with intercellular adhesion molecule-1 expression. Kidney Int. 1996;50:526-537.
48. Opelz G, Dohler B. Multicenter analysis of kidney preservation. Transplantation. 2007;83:247-253.
49. Halloran PF, Homik J, Goes N, et al. The "injury response": a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc. 1997;29:79-81.
50. Salahudeen AK, Haider N, May W. Cold ischemia and the reduced long-term survival of cadaveric renal allografts. Kidney Int. 2004;65:713-718.
51. Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2010:CD003897.
52. Breidenbach WCRK, Blair B, Burns C, et al. Transplant Arteriopathy in Clinical Hand Transplantation. Valencia, Spain: 9th Meeting of the International Hand and Composite Tissue Allotransplantation Society; 2009:11-12.
53. Margreiter R, Klempnauer J, Neuhaus P, et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant. 2008;8:1480-1485.
54. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant. 2005;5:2496-2503.
55. Schneeberger S, Landin L, Kaufmann C, et al. Alemtuzumab: key for minimization of maintenance immunosuppression in reconstructive transplantation? Transplant Proc. 2009;41:499-502.
56. Lanzetta M, Petruzzo P, Vitale G, et al. Human hand transplantation: what have we learned? Transplant Proc. 2004;36:664-668.
57. Schneeberger S, Gorantla VS, Hautz T, et al. Immunosuppression and rejection in human hand transplantation. Transplant Proc. 2009;41:472-475.
58. Cendales LC, Kanitakis J, Schneeberger S, et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant. 2008;8:1396-1400.
59. Landin L, Cavadas PC, Rodriguez-Perez JC, et al. Improvement in renal function after late conversion to sirolimus-based immunosuppression in composite tissue allotransplantation. Transplantation. 2010;90:691-692.
60. Schneeberger S, Ninkovic M, Piza-Katzer H, et al. Status 5 years after bilateral hand transplantation. Am J Transplant. 2006;6:834-841.
61. Bonatti H, Brandacher G, Margreiter R, et al. Infectious complications in three double hand recipients: experience from a single center. Transplant Proc. 2009;41:517-520.
62. Landin L, Cavadas PC, Nthumba P, et al. Preliminary results of bilateral arm transplantation. Transplantation. 2009;88:749-751.
63. Ravindra K, Buell J, Kaufman C, et al. Steroid Free Immunosuppression in Hand Transplantation: First Large Series in World Literature. Boston, MA: American Transplant Congress; 2009:128.
64. Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol. 2010;6:711-721.
65. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet. 1997;350:1729-1733.
66. De Otero J, Gavalda J, Murio E, et al. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis. 1998;26:865-870.
67. Jones NF, Schneeberger S. Arm transplantation: prospects and visions. Transplant Proc. 2009;41:476-480.
68. Huang WC, Lin JY, Wallace CG, et al. Vascularized bone grafts within composite tissue allotransplants can autocreate tolerance through mixed chimerism with partial myeloablative conditioning: an experimental study in rats. Plast Reconstr Surg. 2010;125:1095-1103.
69. Granger DK, Briedenbach WC, Pidwell DJ, et al. Lack of donor hyporesponsiveness and donor chimerism after clinical transplantation of the hand. Transplantation. 2002;74:1624-1630.
70. Mundinger GS, Nam AJ, Hui-Chou HG, et al. Nonhuman primate model of fibula vascularized composite tissue allotransplantation demonstrates donorrecipient bony union. Plast Reconstr Surg. 2011;128:1193-1204.
71. Kanitakis J, Jullien D, Petruzzo P, et al. Clinicopathologic features of graft rejection of the first human hand allograft. Transplantation. 2003;76:688-693.
72. Unadkat JV, Schneeberger S, Horibe EH, et al. Composite tissue vasculopathy and degeneration following multiple episodes of acute rejection in reconstructive transplantation. Am J Transplant. 2010;10:251-261.i